A Phase 4 interventional study of Pravastatin and Placebo in ADPKD and Autosomal Dominant Polycystic Kidney, sponsored by University of Colorado, Denver. Active, not recruiting at 1 site in United States. Open to participants aged 25 Years to 60 Years. Per ClinicalTrials.gov, last updated 2025-05-08.
Sponsored by University of Colorado, Denver · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Polycystic Kidney, Autosomal Dominant by University of Colorado, Denver — 1 open to participants now, 5 under way, none of them phase 3. Polycystic Kidney, Autosomal Dominant · University of Colorado, Denver.
Among the 12 studies in Polycystic Kidney, Autosomal Dominant by University of Colorado, Denver, this one has the largest enrollment of the 11 interventional ones that give a count, is the only one that started in 2017, is one of 2 in phase 4, and was the 5th registered.
185 studies on the registry are indexed under Polycystic Kidney, Autosomal Dominant; 42 are open to participants now.
Browse Polycystic Kidney, Autosomal Dominant studies →1 of the 12 studies in Polycystic Kidney, Autosomal Dominant by University of Colorado, Denver is open now, in 1 country. Recruiting first, the newest first:
University of Colorado, Denver · Sites in United States
Ages 18–65
By country, each count listing its studies:
Of the 30 Polycystic Kidney, Autosomal Dominant studies recruiting now, 8 (27%) set no upper age limit and 19 (63%) stop at 75 or younger; 7 take children under 18; 9 take healthy volunteers.
This study: 25 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 1 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 150 is above the median of 51 across 138 interventional studies indexed under Polycystic Kidney, Autosomal Dominant.
Median enrollment 61 across the 11 interventional studies, 22 across the 1 observational. Of the 7 that completed or were terminated, 5 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of Colorado, Denver is the lead sponsor of 1,545 studies on the registry; 319 are open to participants now.
Of its 147 completed or terminated interventional studies of FDA-regulated products, 92 (63%) have results posted.
2 of the studies in Polycystic Kidney, Autosomal Dominant by University of Colorado, Denver that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04907799University of Colorado, DenverDaily Caloric Restriction in ADPKD | 2027-06-30 |
| NCT06496542University of Colorado, DenverRenal Oxygen Consumption, Insulin Sensitivity, and Daily Caloric Restriction in ADPKD | 2027-08-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 12 studies in Polycystic Kidney, Autosomal Dominant by University of Colorado, Denver, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study plans to learn if pravastatin is helpful in slowing down the progression of kidney disease in adults with autosomal dominant polycystic kidney disease (ADPKD). Pravastatin has been approved by the Food and Drug Administration (FDA) for adults for treatment of hyperlipidemia (high cholesterol levels). The investigators are using pravastatin in this study as an investigational drug for treatment of ADPKD.
This is a randomized, double-blind, placebo-controlled trial designed to assess the efficacy and benefits of pravastatin therapy in adults with ADPKD by evaluating 1) kidney volume as measured by kidney magnetic resonance imaging (MRI); 2) renal blood flow as measured by kidney magnetic resonance angiography (MRA); 3) kidney function as assessed by Glofil-125; 4) plasma and urine protein markers that will allow a better understanding of how pravastatin works in ADPKD; and 5) blood vessel stiffness as measured by carotid-femoral pulse wave velocity. These parameters will be measured at baseline and after 2 years of pravastatin or placebo treatment in 150 patients with ADPKD.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive inactive 40 mg tablets of placebo everyday for 6 weeks. If well tolerated, participants will continue taking inactive 40 mg dose of placebo everyday for 2 years.
Drug: Placebo
Participants will receive 40 mg tablets of pravastatin everyday for 6 weeks. If well tolerated, participants will continue taking 40 mg dose of pravastatin everyday for 2 years.
Drug: Pravastatin
Anti-inflammatory, anti-oxidative stress, and anti-proliferative therapy
Inactive tablet
Change in Total Kidney Volume
Total kidney volume as assessed by renal MRI, at baseline and after 2 years of treatment
Time frame: Baseline, 2 years
Change in Renal Blood Flow
Renal blood flow, as assessed by renal MRA, at baseline and after 2 years of treatment
Time frame: Baseline, 2 years
Change in Kidney Function
Glomerular filtration rate (GFR), as assessed by Glofil-125, at baseline and after 2 years of treatment
Time frame: Baseline, 2 years
Change in Circulating Inflammatory Markers
Plasma levels of inflammatory cytokines and growth factors at baseline and after 2 years of treatment
Time frame: Baseline, 2 years
Change in Circulating Markers of Oxidative Stress
Plasma levels of oxidative stress markers at baseline and after 2 years of treatment
Time frame: Baseline, 2 years
Change in Urinary Epithelial Cells
Urinary epithelial cell protein expression, as assessed by immunofluorescence, at baseline and after 2 years of treatment
Time frame: Baseline, 2 years
Change in Blood Vessel Stiffness
Blood vessel stiffness, as assessed by carotid-femoral pulse wave velocity, at baseline and after 2 years
Time frame: Baseline, 2 years
Plan to share: No
Ran from Aug 2017 to primary completion in Mar 2024, 78 months.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pravastatin
Polycystic Kidney, Autosomal Dominant →
University of Colorado, Denver →